For the clinical relevance and diagnostic value in breast cancer patients, the ROC analyses indicated that the combination usage of TUSC8 and MYLIP might become novel promising biomarkers and targets for breast cancer diagnosis and treatment. This evidence concerns the gene TUSC8 and breast cancer.